Has Sato Pharmaceutical Co., Ltd. received FDA warning letters?

Yes, 1 warning letter on file. See the full history below for each one.

Is this FDA enforcement data for Sato Pharmaceutical Co., Ltd. official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has Sato Pharmaceutical Co., Ltd. had?

Argus HQ has recorded 2 FDA events for Sato Pharmaceutical Co., Ltd.: 1 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Sato Pharmaceutical Co., Ltd.?

The most recent FDA event Argus HQ has on file for Sato Pharmaceutical Co., Ltd. is dated 2026-05-18, with a severity rating of "critical" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

FDA Enforcement History: Sato Pharmaceutical Co., Ltd.

Here's the summary: Argus HQ has recorded 2 FDA events for Sato Pharmaceutical Co., Ltd.: 1 warning letters, 0 recalls, 0 approvals, and 1 inspection 483 observations. These events span from 2025-11-21 to 2026-05-18. The most severe rating Argus HQ has assigned across this history is "critical". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	2
Warning letters	1
Recalls	0
Approval records	0
Form 483 inspection citations	1
Most recent action	May 18, 2026

Enforcement history

On 2026-05-18, Argus HQ recorded an FDA Warning Letter for Sato Pharmaceutical Co., Ltd., rated "critical" severity in Argus HQ's classification: Sato Pharmaceutical Co., Ltd. — CGMP/Drugs/Adulterated/OTC (2026-05-18). On 2025-11-21, Argus HQ recorded an FDA Form 483 inspection citation for Sato Pharmaceutical Co., Ltd., rated "high" severity in Argus HQ's classification: Sato Pharmaceutical Co., Ltd. -- FDA 483: 1 observation (2025-11-21). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Sato Pharmaceutical Co., Ltd. has 2 FDA events on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

Has Sato Pharmaceutical Co., Ltd. received FDA warning letters?: Yes, 1 warning letter on file. See the full history below for each one.
Is this FDA enforcement data for Sato Pharmaceutical Co., Ltd. official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has Sato Pharmaceutical Co., Ltd. had?: Argus HQ has recorded 2 FDA events for Sato Pharmaceutical Co., Ltd.: 1 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Sato Pharmaceutical Co., Ltd.?: The most recent FDA event Argus HQ has on file for Sato Pharmaceutical Co., Ltd. is dated 2026-05-18, with a severity rating of "critical" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: May 18, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Enforcement History: Sato Pharmaceutical Co., Ltd.. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/sato-pharmaceutical-co-ltd

MLA

"FDA Enforcement History: Sato Pharmaceutical Co., Ltd.." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/sato-pharmaceutical-co-ltd.

Chicago

Argus HQ Research. "FDA Enforcement History: Sato Pharmaceutical Co., Ltd.." Digital Empire Holdings LLC. Accessed August 29, 2026. https://argushq.ai/company/sato-pharmaceutical-co-ltd.

BibTeX

@misc{argushq_argushq_ai_company_sato_pharmaceutical_co_ltd_2026,
  title = {FDA Enforcement History: Sato Pharmaceutical Co., Ltd.},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/sato-pharmaceutical-co-ltd},
  note = {Accessed: August 29, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗